CoChat

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib

Open access
Masiello, David, Gorospe, Gerry, Yang, Allen S · 2009 · Journal of Hematology & Oncology

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Tyrosine kinase inhibitors (TKIs) like dasatinib and nilotinib are indicated as second-line treatment for chronic myeloid leukemia resistant or intolerant to the current first-line TKI imatinib. These are agents are well tolerated, but potent and as such should be monitored for potentially serious side-effects like fluid retention and pleural effusions. Here we present key clinical trial data and safety considerations for all FDA approved TKIs in context for effective management of fluid retention and pleural effusions. Altering the dasatinib regimen from 70 mg twice daily to 100 mg daily reduces the risk of pleural effusion for patients taking dasatinib. Should pleural effusion develop, dasatinib should be interrupted until the condition resolves. Patients with a history of pleural effusion risk factors should be monitored closely while taking dasatinib. Patients receiving imatinib and nilotinib are not without risk of fluid retention. All patients should also be educated to recognize and report key symptoms of fluid retention or pleural effusion. Pleural effusions are generally managed by dose interruption/reduction and other supportive measures in patients with chronic myeloid leukemia receiving dasatinib therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1756-8722-2-46

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The management of pleural effusion emerging on treatment with dasatinib. aBMS, 2009 [13]. bNCCN, 2009 [2]. Abbreviation: ANC = absolute neutrophil count
Figure 1 The management of pleural effusion emerging on treatment with dasatinib. aBMS, 2009 [13]. bNCCN, 2009 [2]. Abbreviation: ANC = absolute neutrophil countCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 2

  1. Le Coutre P, Larson R, Kantarjian H: A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant or -intolerant patients with Philadelphia-positive chronic myelogenous leukemia in accelerated phase. Haematologica. 2007, 92 (suppl 1): 557-
  2. Ottmann O, Larson R, Kantarjian H: Nilotinib monotherapy in patients with imatinib-resistant or -intolerant Ph+ chronic myelogenous leukemia (CML) in blast crisis or relapsed/refractory Ph+ acute lymphoblastic leukemia. Haematologica. 2007, 92 (suppl 1): 556-

Cited by

See all 69

Metadata

Authors
Masiello, D., Gorospe, G., & Yang, A. S.
Affiliations
University of Southern California (US)
Corresponding author
Yang, Allen S
Venue
Journal of Hematology & Oncology
Published
2009-11-12
Volume
2
Issue
1
Pages
46-46
ISSN
1756-8722 (ISSN-L)
OpenAlex
W2120222130
Cited by
66
References
30
Citations by year
2026: 3 · 2024: 1 · 2023: 3 · 2022: 6 · 2021: 6 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 6 · 2016: 2 · 2015: 8 · 2014: 2 · 2013: 4 · 2012: 8
FWCI
3.78
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/2.0 (tdm)
Locations
  • Journal of Hematology & Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Kenneth T. and Eileen L. Norris Foundation
  • Bristol-Myers Squibb
  • Celgene
  • Eisai
Topics
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
fluid retention, pleural effusion, dasatinib, tyrosine kinase inhibitors, chronic myeloid leukemia, nilotinib, imatinib, dose interruption, dose reduction, adverse drug reactions, second-line therapy
MeSH terms
Dasatinib, Algorithms, Humans, Pleural Effusion, Protein-Tyrosine Kinases, Pyrimidines, Thiazoles, Water-Electrolyte Imbalance, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Incidence, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. https://app.cochat.ai/papers/10.1186/1756-8722-2-46
The paper
Masiello, D., Gorospe, G., & Yang, A. S. (2009). The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. Journal of Hematology & Oncology. https://doi.org/10.1186/1756-8722-2-46

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.